Synergy Spine Solutions Completes Enrollment in Synergy Disc 2-Level IDE Clinical Trial
Key Insights
Synergy Spine Solutions (search) has completed patient enrollment in its U.S. 2-Level IDE clinical trial for the Synergy Disc (search).
The trial evaluates the safety and effectiveness of the Synergy Disc (search) compared to anterior cervical discectomy and fusion (ACDF (search)) for degenerative disc disease (search).
The Synergy Disc (search) features a lordotic core designed to maintain or restore sagittal alignment, potentially expanding TDR indications.
Synergy Spine Solutions (search) Ltd, an orthopedic medical device developer focused on artificial cervical disc replacement, announced the completion of patient enrollment in its U.S. 2-Level IDE clinical trial. This trial aims to evaluate the safety and effectiveness of the Synergy Disc (search) artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF (search)). The study focuses on treating symptomatic degenerative disc disease (search) at two contiguous levels from C3 to C7.
The multi-center, prospective, non-randomized, historically controlled study is being conducted on 200 patients across 24 clinical sites in the U.S. under a U.S. Investigational Device Exemption (IDE).
Surgeon Perspectives on Synergy Disc
Dr. Pierce Nunley, an orthopedic spine surgeon at the Spine Institute of Louisiana, noted the ease and safety of use in surgery. He highlighted the unique lordotic core of the Synergy Disc (search), designed to maintain or restore sagittal alignment. "The Synergy Disc is unique in that it is the only disc that offers a lordotic core designed to maintain or restore sagittal alignment," he stated.
Dr. Armen Khachatryan, an orthopedic spine surgeon based in West Jordan, Utah, emphasized the innovative design elements of the Synergy Disc (search), including lordotic core options, titanium alloy endplates, and a highly stable biomechanical core. "The Synergy Disc represents a significant advancement in spinal surgery, featuring innovative design elements such as lordotic core options, titanium alloy endplates, and a highly stable biomechanical core," said Dr. Khachatryan. He also anticipates that upon FDA approval, the Synergy Disc will be indicated for use in patients with prior cervical fusion, offering surgeons more options for disc arthroplasty.
Significance of Enrollment Completion
The completion of patient enrollment in the 2-Level IDE clinical trial marks a crucial step for Synergy Spine Solutions (search) in obtaining US FDA regulatory approval. Josh Butters, CEO of Synergy Spine Solutions, expressed his excitement, stating, "This is an extremely exciting achievement for the entire Synergy team and its shareholders. We completed enrollment ahead of plan and in about half of the time that it took to enroll our 1-Level IDE trial."
Synergy Disc Design and Potential Impact
The Synergy Disc (search) is designed to restore both motion and alignment to the spine. Its unique design and the anticipated clinical results are expected to demonstrate significant advantages, potentially growing the cervical TDR and overall motion preservation market. The device features a straightforward implantation technique, making it a versatile option for both single and two-level procedures.